Aarti Drugs Limited announced its audited financial results for the Quarter and Nine Months ended December 31, 2025. For the third quarter of FY26, the company reported a consolidated revenue of ₹602.9 crore, an increase of 8% year-on-year compared to ₹557.1 crore in Q3 FY25. EBITDA stood at ₹56.3 crore, a decrease of 10% year-on-year, with EBITDA margins at 9.3%. Profit After Tax (PAT) surged by 58% to ₹40.5 crore, up from ₹25.7 crore in Q3 FY25, resulting in a PAT margin of 6.7%. For the nine months ended FY26, consolidated revenue grew by 8% YoY to ₹1,846.6 crore. EBITDA increased by 9% YoY to ₹215.0 crore, with margins at 11.6%. PAT for the nine-month period rose significantly by 49% to ₹139.7 crore, compared to ₹94.0 crore in the same period last year, with a PAT margin of 7.6%. The API segment revenue saw a marginal decline of 1% YoY to ₹454.3 crore, while Formulations revenue grew by 59% YoY to ₹76.4 crore, and Specialty Chemicals revenue increased by 51% YoY to ₹51.1 crore. The standalone business contributed 88% to the consolidated revenue, with domestic revenue being flat YoY and export revenue increasing by 6% YoY. Mr. Adhish Patil, CFO & COO, highlighted the steady performance driven by domestic market traction and strong growth in export formulations. He noted that the EBITDA contraction was due to transient market dynamics and commissioning costs for new facilities. The backward integration plant in Sayakha for methyl amines achieved 30% capacity utilization in its first quarter and is expected to reach 50% by March/April 2026, aiming for 100% self-reliance for Metformin requirements within 6-8 months. The Salicylic Acid plant in Tarapur has scaled to over 300 tonnes per month, and a downstream Salicylates line is under implementation. Regulatory approvals and certifications are progressing as planned, with preparations for European approvals underway.
